EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Mizuho Securities Starts EyePoint Pharmaceuticals, Inc. (EYPT) at Buy
November 1, 2023 4:05 PM EDTMizuho Securities analyst Graig Suvannavejh initiates coverage on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) with a Buy rating and a price target of $20.00.
The analyst comments "We initiate on EYPT at Buy/$20 (implies ~200% upside). EYPT is advancing EYP-1901 as a novel treatment for retinal diseases,... More
